Multispecific WNT Surrogate Molecules for Fzd/LRP5/6 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack binding moieties that specifically bind to Fzd and LRP receptors to modulate Wnt signaling pathways with tissue and functional specificity, and there is a need for creating binding moieties with specific ratios of co-receptors to confer tissue and functional specificity.
Innovation Solution
Development of multispecific Wnt surrogate molecules with multiple regions that bind to different sets of Fzd receptors and LRP5/6, utilizing specific structural formats to modulate Wnt signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If binding moieties are designed to bind to multiple Fzd and LRP receptors with specific ratios, then tissue and functional specificity are enhanced, but the complexity of the binding moiety structure increases
Solution Approach 1:
The binding moiety is divided into multiple independent binding regions, with each region specifically designed to bind to different Fzd and/or LRP receptor epitopes. This segmentation allows the complex multispecific binding function to be achieved through modular components, where each region can be optimized independently for its specific target while contributing to the overall tissue and functional specificity.
Solution Approach 2:
The binding moiety is designed as a universal platform that can simultaneously bind to multiple different Fzd and LRP receptors through its multiple binding regions. This multi-functionality enables a single binding moiety to modulate multiple Wnt signaling pathways concurrently, achieving tissue and functional specificity without requiring separate binding moieties for each target.
2Manufacturing precision
If multiple binding regions are incorporated to target different Fzd and LRP receptors, then signaling modulation specificity is improved, but the manufacturing complexity increases
Solution Approach 1:
The binding moiety is constructed from multiple independently designed binding regions that can be manufactured separately and then assembled. Each binding region targets specific Fzd and/or LRP receptors, allowing for precise control over the signaling modulation pathway. This segmented approach facilitates standardized manufacturing processes while maintaining the precision required for multispecific receptor targeting.
3Object-affected harmful factors
If a single binding moiety binds to multiple Fzd and LRP receptors simultaneously, then off-target effects are reduced, but the structural complexity of the binding moiety increases
Solution Approach 1:
The binding moiety employs multiple segmented binding regions, each specifically targeted at different Fzd and/or LRP receptors. This segmentation ensures that each region contributes to binding a specific target receptor, thereby reducing off-target effects through precise receptor selectivity while managing structural complexity through modular design.
Solution Approach 2:
Each binding region within the binding moiety is designed with local quality specific to its target Fzd and/or LRP receptor epitope. This local optimization ensures high affinity and specificity for each target, minimizing off-target binding. The local quality of each binding region is tailored to its specific function, allowing the overall moiety to achieve broad specificity without compromising individual binding interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Wnt surrogate molecules selectively activate specific combinations of Fzd receptors, reducing off-target effects and enhancing therapeutic efficacy for treating various diseases and disorders associated with Wnt signaling.
Implementation Method 1
the Wnt surrogate molecule comprises: (i) two regions that each specifically bind to a set of one or more Fzd receptor epitopes (Fzd binding regions)... and (ii) two regions that each specifically bind to a Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) and/or a LDL receptor-related protein 6 (LRP6)
Data Source
Figure 1A~1AM
Figure 2A~2D
Figure 3A
AI summary
The present disclosure provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.